Information de reference pour ce titreAccession Number: | 01451459-200509011-00023.
|
Author: | Glass, Roger I. 1; Bresee, Joseph S. 1; Turcios, Reina 1; Fischer, Thea K. 1; Parashar, Umesh D. 1; Steele, Duncan A. 2
|
Institution: | (1) Viral Gastroenteritis Section, Centers for Disease Control and Prevention, Atlanta, Georgia (2) Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland
|
Title: | |
Source: | Journal of Infectious Diseases. 192 (Suplement 1):S160-S166, September 1, 2005.
|
Abstract: | : For the past 2 decades, rotavirus infection, the most common cause of severe diarrhea in children, has been a priority target for vaccine development. This decision to develop rotavirus vaccines is predicated on the great burden associated with fatal rotavirus disease (i.e., 440,000 deaths/year), the firm scientific basis for developing live oral vaccines, the belief that increased investment in development at this time could speed the introduction of vaccines in developing countries, and the appreciation that implementation of a vaccine program should result in a measurable decrease in the number of hospitalizations and deaths associated with rotavirus disease within 2-3 years. RotaShield (Wyeth-Ayerst), the first rotavirus vaccine licensed in the United States, was withdrawn after 9 months because of a rare association of the vaccine with the development of intussusception. In the developing world, this vaccine could still have had a measurable effect, because the benefits of preventing deaths due to rotavirus disease would have been substantially greater than the rare risk of intussusception. Two live oral vaccines being prepared by GlaxoSmithKline and Merck have completed large-scale clinical trials. The GlaxoSmithKline vaccine has been licensed in Mexico and the Dominican Republic, and the Merck vaccine could be licensed in the United States within 1 year; several other candidate vaccines are in earlier stages of testing. However, many challenges remain before any of these vaccines can be incorporated into childhood immunization programs in the developing world. First, vaccine efficacy, which has already been demonstrated in children in industrialized and middle-income countries, needs to be proven in poor developing countries in Africa and Asia. The safety of vaccines with regard to the associated risk of intussusception must be demonstrated as well. Novel financing strategies will be needed to ensure that new vaccines are affordable and available in the developing world. Decision makers and parents in developing countries need to know about this disease that has little name recognition and is rarely diagnosed. Finally, for the global effort toward the prevention of rotavirus disease to be successful, special efforts will be required in India, China, and Indonesia, because one-third of all deaths due to rotavirus disease occur in these countries, and because these countries depend almost entirely on vaccines manufactured domestically.
(C) Copyright Oxford University Press 2005.
|
References: | 1. Kosek M, Bern C, Guerrant RI. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ 2003; 81:197-204.
2. Villa S, Guiscafre H, Martinez H, Munoz O, Gutierrez G. Seasonal diarrhoeal mortality among Mexican children. Bull World Health Organ 1999; 77:375-80.
3. Bresee J, Glass RI, Ivanoff B, Gentsch J. Current status and future priorities for rotavirus vaccine development, evaluation, and implementation in developing countries. Vaccine 1999; 17:2207-22.
4. Glass RI, Stoll BJ. The protective effect of human milk against diarrhea: a review of studies from Bangladesh. Acta Paediatr Scand Suppl 1989; 351:131-6.
5. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infection in infants as protection against subsequent infections. N Engl J Med 1996; 335:1022-8.
6. World Health Organization (WHO). Report of the meeting on future directions for rotavirus vaccine research in developing countries. WHO/V&B/00.23 2000. Geneva: WHO,.
7. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9:565-72.
8. Parashar UD, Bresee JS, Glass RI. The global burden of diarrhoeal disease in children. Bull World Health Organ 2003; 81:236.
9. Cunliffe NA, Kilgore PE, Bresee JS, et al. Epidemiology of rotavirus diarrhoea in Africa: a review to assess the need for rotavirus immunization. Bull World Health Organ 1998; 76:525-37.
10. Steele AD, Peenze I, de Beer MC, et al. Anticipating rotavirus vaccines: epidemiology and surveillance of rotavirus in South Africa. Vaccine 2003; 21:354-60.
11. O'Ryan M, Perez-Schael I, Mamani N, et al. Rotavirus-associated medical visits and hospitalizations in South America: a prospective study at three large sentinel hospitals. Pediatr Infect Dis J 2001; 20:685-93.
12. Parashar UD, Holman RC, Clarke MJ, Bresee JS, Glass RI. Hospitalizations associated with rotavirus diarrhea in the United States, 1993 through 1995: surveillance based on the new ICD-9-CM rotavirus-specific diagnostic code. J Infect Dis 1997; 177:13-7.
13. Tucker AW, Haddix AC, Bresee JS, Holman RC, Parashar UD, Glass RI. Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA 1998; 279:1371-6.
14. Kilgore PE, Holman RC, Clarke MJ, Glass RI. Trends of diarrheal disease-associated mortality in US children, 1968 through 1991. JAMA 1995; 274:1143-8.
15. Bishop R, Barnes G, Cipriani E, Lund J. Clinical immunity after neonatal rotavirus infection: a prospective longitudinal study in young children. N Engl J Med 1983; 309:72-6.
16. Vesikari T, Isolauri E, D'Hondt E, Delem A, Andre FE, Zissis G. Protection of infants against rotavirus diarrhea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984; 1:977-81.
17. De Mol P, Zissis G, Butlzler JP, Mutwewingabo A, Andre FE. Failure of live, attenuated oral rotavirus vaccine. Lancet 1986; 2:108.
18. Hanlon P, Marsh V, Jobe O, et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1987; 1:1342-5.
19. Lanata CF, Black RE, del Aguila R, et al. Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. J Infect Dis 1989; 159:452-9.
20. Kapikian AZ. In: Kapikian AZ. Rhesus rotavirus-based human rotavirus vaccines and observations on selected non-Jennerian approaches to rotavirus vaccination. Viral infections of the gastrointestinal tract. 2nd ed.. New York: Marcel Dekker 1993:443-70.
21. Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines: report of the national multicenter trial. Pediatrics 1996; 97:7-13.
22. Santosham M, Moulton LH, Reid R, et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr 1997; 131:632-8.
23. Joensuu J, Koskenniemi E, Pang X-L, Vesikari T. Randomised, double-blind, placebo controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997; 350:1205-9.
24. Perez-Schael I, Guntinas MJ, Perez M, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997; 337:1181-7.
25. Centers for Disease Control and Prevention. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. MMWR Recomm Rep 1999; 48(RR-2):1-20.
26. Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine, United States, 1998-1999. MMWR Morb Moral Wkly Rep 1999; 48:577-81.
27. Centers for Disease Control and Prevention. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 1999; 48:1007.
28. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344:564-72.
29. Peter G, Myers MG. Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics 2002; 110:e67.
30. Simonsen L, Morens DM, Elixhauser A, Gerber M, Van Raden M, Blackwelder WC. Effect of rotavirus vaccination programme on trends in admission of infants to hospital for intussusception. Lancet 2001; 358:1224-7.
31. Melton L. Lifesaving vaccine caught in an ethical minefield [letter]. Lancet 2000; 356:318.
32. Glass RI, Bresee JS, Parashar UD, Jiang B, Gentsch J. The future of rotavirus vaccines: a major setback leads to new opportunities. Lancet 2004; 363:1547-50.
33. Lynch M, Bresee JS, Gentsch JR, Glass RI. Rotavirus vaccines. Curr Opin Infect Dis 2000; 13:495-502.
34. Perez-Schael I, Salinas B, Linhares AC, et al. Protective efficacy of an oral human rotavirus (HRV) vaccine in Latin American infants. Progam and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego) 2002. Washington, DC: American Society for Microbiology.
35. Eichelberger MC, Sperber E, Wagner M, et al. Clinical evaluation of a single oral dose of human-bovine (UK) reassortant rotavirus vaccines Wa x UK (P1A[8],G6) and Wa x (DS-1 x UK) (P1A[8],G2). J Med Virol 2002; 66:407-16.
36. Georges-Courbot MC, Monges J, Siopathis MR, et al. Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa. Res Virol 1991; 142:405-11.
37. Su-Arehawaratana P, Singharaj P, Taylor DN, et al. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J Infect Dis 1992; 165:1042-8.
38. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991; 13:926-39.
39. World Health Organization (WHO). Vaccine research and development: rotavirus vaccines for developing countries 1997. Geneva: WHO.
40. World Health Organization (WHO). Generic protocols (i) hospital-based surveillance to estimate the burden of rotavirus gastroenteritis in children and (ii) a community based survey on utilization of health care services for gastroenteritis in children. WHO/V&B/02 2002; 15. Geneva: WHO. 1-67.
41. Glass RI, Bahn MK, Ray P, et al. Development of candidate rotavirus vaccines derived from neonatal strains in India. J Infect Dis 2005; 192(Suppl 1)S30-5 (in this issue).
|
Language: | English.
|
Document Type: | Supplement Articles.
|
ISSN: | 0022-1899
|
DOI Number: | https://dx.doi.org/10.1086/43150...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|